Cabergoline CAS 81409-90-7

1. Cabergoline is an ergot derivative primarily used as a long-acting dopamine receptor agonist for the treatment of hyperprolactinemic disorders, including idiopathic hyperprolactinemia and prolactin-secreting pituitary adenomas (prolactinomas), in adults .
2. Cabergoline is also indicated for the management of symptoms of Parkinsonian syndrome, functioning as either monotherapy during initial treatment or as an adjunct to levodopa therapy in advanced disease stages .
3. Cabergoline CAS 81409-90-7 exerts its therapeutic effect by stimulating dopamine D2 receptors on pituitary lactotrophs, which inhibits the secretion of prolactin and restores normal gonadal function .
4. The recommended starting dosage of Cabergoline is 0.25 mg orally twice weekly, with titration at intervals of no less than 4 weeks to achieve normal serum prolactin levels, up to a maximum dosage of 1 mg twice weekly .

1. Cabergoline must be stored in a tightly sealed container at room temperature, away from heat, moisture, and direct light, and should be kept out of the reach of children .
2. Cabergoline CAS 81409-90-7 is contraindicated in patients with uncontrolled hypertension, known hypersensitivity to ergot derivatives, history of cardiac valvular disorders or pericardial fibrosis, and history of pleural, pulmonary, or retroperitoneal fibrotic disorders .
3. Prior to initiating Cabergoline, patients must undergo a cardiovascular evaluation including an echocardiogram to assess for valvular disease; if valvulopathy is detected, Cabergoline should not be administered .
4. Cabergoline is not recommended for concomitant use with D2-antagonists such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide due to potential drug interactions that may reduce efficacy .

1. Isolate the spill area immediately, ensure adequate ventilation, and remove all sources of ignition when Cabergoline is released, wearing full personal protective equipment including chemical-resistant gloves, safety goggles, and suitable dust respirator .
2. Collect Cabergoline CAS 81409-90-7 by sweeping or vacuuming without creating dust using non-sparking tools, and place into suitable closed containers for disposal according to local regulations .
3. Avoid creating dust clouds during cleanup to prevent respiratory exposure, and decontaminate surfaces using appropriate methods, ensuring the product does not enter drains or water courses .
4. Dispose of collected material as hazardous waste according to local, state, and federal environmental regulations through licensed chemical destruction or controlled incineration .

1. Cabergoline is not classified as highly flammable but may decompose under fire conditions, emitting toxic fumes including carbon monoxide, carbon dioxide, and nitrogen oxides (NOx) .
2. Use Cabergoline CAS 81409-90-7 dry chemical powder, carbon dioxide, alcohol-resistant foam, or water spray to extinguish fires involving the product, selecting the extinguishing media most appropriate for surrounding materials .
3. Firefighters should wear self-contained breathing apparatus in pressure-demand, MSHA/NIOSH approved, and full protective gear when handling burning Cabergoline due to hazardous decomposition gases generated by thermal decomposition .
4. During combustion, may emit irritant and toxic fumes; move containers from the fire area if safe to do so, cool exposed containers with water spray from a protected location, and contain fire runoff to prevent environmental contamination and pollution .